Latest Commercial Operations News

Elixir Energy is set to resume production testing at its Diona-1 well this quarter and prepare for the high-impact Lorelle-3 appraisal well drilling in January 2026, aiming to unlock significant gas resources in Queensland’s Taroom Trough.

Pursuit Minerals progresses its Rio Grande Sur lithium project with a refined commercial plan and feasibility study, while expanding into gold through the Sascha Marcelina acquisition. A recent $4 million placement strengthens its financial position for growth.

Murray Cod Australia Ltd reports a robust start to FY26 with a 45% increase in sales and a $17 million capital raise, driven by expanded production and market access including new Halal certification.

Artrya Limited has secured FDA clearance for its Salix Coronary Plaque module and raised $80 million to fuel its U.S. commercial expansion, marking a pivotal step in its transition from development to revenue generation.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.

Viridis Mining and Minerals has secured a prime site and finalized key contracts for its Rare Earth Research and Processing Centre in Brazil, positioning itself as a critical Western-aligned rare earth supplier amid tightening Chinese export controls.

Jade Gas Holdings has raised A$5 million through a placement to advance commercial gas production at its Red Lake field, with a follow-up Share Purchase Plan aiming to raise an additional A$2.1 million.

Frontier Energy unveils an ambitious multi-stage expansion of its Waroona Renewable Energy Project, targeting 1GW of solar and 660MW of battery storage to support Western Australia’s coal phase-out.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Memphasys Limited has secured $0.84 million through a placement and announced a rights issue to raise up to $1.12 million, sharply cutting operating costs to accelerate commercialisation and manufacturing scale-up of its Felix™ bioseparation system.